A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPD

Introduction The Fostair® 100/6 (BDP/FF) pressurized metered-dose inhaler, delivering an extrafine formulation, is licensed for asthma and COPD in the UK. However, its real-life effectiveness for COPD has not been evaluated. This study compared the clinical effectiveness of BDP/FF against other licensed ICS/LABA combination inhalers: the Seretide® Accuhaler® (FP/SAL) and the Symbicort® Turbohaler® (BUD/FF). Methods A matched historical cohort study was conducted using records of patients with diagnostic codes for COPD from the Optimum Patient Care Research Database (OPCRD). Patients who had received BDP/FF as their first ICS/LABA were matched 1:1 with patients who had received FP/SAL or BUD/FF, resulting in two matched comparisons. Additional analysis was conducted on patients who had never had diagnostic codes for asthma. Noninferiority in terms of the proportion of patients with moderate/severe COPD exacerbations on the different inhalers in the following year was assessed. Noninferiority was achieved if the upper CI limit were ≤1.2. Results This study included 537 and 540 patient pairs in the BDP/FF vs FP/SAL cohort and the BDP/FF vs BUD/FF cohort, respectively. The proportion of patients with COPD exacerbations in the BDP/FF group was not significantly different from either the FP/SAL (68.7% vs 70.2%, AOR 0.89, 95% CI 0.67–1.19) or BUD/FF group (68.5% vs 69.4%, AOR 0.79, 95% CI 0.58–1.08). Noninferiority of BDP/FF in preventing COPD exacerbations was fulfilled in both comparisons. In patients without asthma, BDP/FF was also noninferior to BUD/FF (proportion with COPD exacerbations, 67.8% vs 64.7%, AOR 0.79, 95% CI 0.51–1.1997). Additionally, a significantly lower proportion of patients prescribed BDP/FF had COPD exacerbations than FP/SAL (64.8% vs 73.7%, AOR 0.64 95% CI 0.43–0.96). Conclusion Initiating ICS/LABA treatment of COPD with extrafine-formulation BDP/FF was noninferior in preventing moderate/severe exacerbations compared to FP/SAL and BUD/FF.

[1]  N. Team.  Chronic obstructive pulmonary disease in over 16s: diagnosis and management , 2018 .

[2]  Dave Singh,et al.  The efficacy of extrafine beclomethasone dipropionate–formoterol fumarate in COPD patients who are not “frequent exacerbators”: a post hoc analysis of the FORWARD study , 2017, International journal of chronic obstructive pulmonary disease.

[3]  D. Postma,et al.  Risk of pneumonia in obstructive lung disease: A real-life study comparing extra-fine and fine-particle inhaled corticosteroids , 2017, PloS one.

[4]  Nicholas Moore,et al.  Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients , 2017, European Respiratory Journal.

[5]  J. Virchow,et al.  Non-persistence and non-adherence to long-acting COPD medication therapy: A retrospective cohort study based on a large German claims dataset. , 2017, Respiratory medicine.

[6]  D. Price,et al.  Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: Effect of drug, dose, and device. , 2016, Respiratory medicine.

[7]  D. Postma,et al.  Effectiveness of initiating extrafine-particle versus fine-particle inhaled corticosteroids as asthma therapy in the Netherlands , 2016, BMC Pulmonary Medicine.

[8]  P. Montuschi,et al.  Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping. , 2014, Drug discovery today.

[9]  N. Scichilone,et al.  Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD , 2014, Patient related outcome measures.

[10]  M. Decramer,et al.  Withdrawal of inhaled glucocorticoids and exacerbations of COPD. , 2014, The New England journal of medicine.

[11]  D. Steinke,et al.  A comparison of medication adherence/persistence for asthma and chronic obstructive pulmonary disease in the United Kingdom , 2014, International journal of clinical practice.

[12]  D. Price,et al.  Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns , 2014, International journal of chronic obstructive pulmonary disease.

[13]  P. Jones,et al.  Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. , 2014, Respiratory medicine.

[14]  Dave Singh,et al.  Extrafine Beclomethasone/formoterol compared to Fluticasone/salmeterol Combination Therapy in COPD , 2014, BMC Pulmonary Medicine.

[15]  Mike Thomas,et al.  Quality standards for real-world research. Focus on observational database studies of comparative effectiveness. , 2014, Annals of the American Thoracic Society.

[16]  D. Postma,et al.  Integrating real-life studies in the global therapeutic research framework. , 2013, The Lancet. Respiratory medicine.

[17]  D. Price,et al.  Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients , 2013, Primary care respiratory journal : journal of the General Practice Airways Group.

[18]  P. Poole,et al.  Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. , 2013, The Cochrane database of systematic reviews.

[19]  N. Banik,et al.  Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD. , 2013, Respiratory medicine.

[20]  D. Price,et al.  Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. , 2012, Primary care respiratory journal : journal of the General Practice Airways Group.

[21]  D. Lechuga‐Ballesteros,et al.  Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers. , 2012, Langmuir : the ACS journal of surfaces and colloids.

[22]  Marco Lodi,et al.  Inhaler mishandling remains common in real life and is associated with reduced disease control. , 2011, Respiratory medicine.

[23]  P. Kuna,et al.  Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. , 2010, Respiratory medicine.

[24]  D. Price,et al.  The use of roflumilast in COPD: a primary care perspective. , 2010, Primary care respiratory journal : journal of the General Practice Airways Group.

[25]  David Price,et al.  Choosing inhaler devices for people with asthma: current knowledge and outstanding research needs. , 2010, Respiratory medicine.

[26]  A. Paternó,et al.  Effects of extra‐fine inhaled beclomethasone/formoterol on both large and small airways in asthma , 2010, Allergy.

[27]  F. Ram,et al.  Inhaler devices for the treatment of asthma and chronic obstructive airways disease (COPD) , 2002, Quality & safety in health care.

[28]  A V Prochazka,et al.  The assessment of refill compliance using pharmacy records: methods, validity, and applications. , 1997, Journal of clinical epidemiology.